

# Agenda

## Chinese American Hematologist Oncologist Network (CAHON) 美国华裔血液及肿瘤专家学会

### Oct 3<sup>rd</sup> CAHON Annual Dinner Meeting (for CAHON members, faculty speakers and invited guests only)

- 6:00pm: Welcome, Reception Dinner and Introduction of CAHON Members
- 7:00pm: CAHON Accomplishments
- 7:20pm: CAHON JIA Award Presentation
- 7:30pm: CAHON OSA Award Presentation
- 7:45pm: CAHON LAA Award Presentation
- 7:55pm: CAHON New Initiatives and Business meeting
- 8:30pm: Networking



# CAHON member self-introduction

## Wenru Song, MD, PhD



Wenru Song is a founding board member, current Board Chair and the past-president of the Chinese American Hematologist and Oncologist Network (CAHON). He is currently Vice President of Immuno-Oncology at AstraZeneca. He graduated from Shandong Medical University in China, received PhD in Texas A&M University, postdoc training in Cornell University Medical Center, medical residency at Montefiore Medical Center/Albert Einstein College of Medicine, and medical oncology fellowship at Stanford University. He is a member of ASH Foundation and Development Committee and a member of the International Affairs Committee of ASCO. Dr. Song serves in the Editorial Board of *Journal of Hematology and Oncology* and *Chinese Clinical Oncology*.

# CAHON member self-introduction

Jing-Zhou Hou, MD, PhD



Jing-Zhou Hou is a founding member, and current president of the Chinese American Hematologist and Oncologist Network (CAHON). He is a clinical assistant professor at University of Pittsburgh. He graduated from Henan Medical University in China, received PhD from Tulane University, postdoc training in NCI/NIH, medical residency in Ohio, and Hematology and Oncology fellowship at Stanford, and BMT clinical research fellow at Stanford University. Dr. Hou serves in the Editorial Board of *Journal of Hematology and Oncology*. Dr. Hou specializes in hematological malignancies and BMT. He served as the co-chair of lymphoma clinical pathway committee from 2008 to 2015 at UPMC Cancer Centers, now Via Oncology.